A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma

Last updated: January 27, 2025
Sponsor: Sight Sciences, Inc.
Overall Status: Terminated

Phase

4

Condition

Open Angle Glaucoma

Glaucoma

Treatment

OMNI Surgical System

Latanoprost plus adjunctive glaucoma medication

Clinical Study ID

NCT06407973
09074
  • Ages > 45
  • All Genders

Study Summary

A Randomized Clinical Trial of Ab Interno Canaloplasty and Trabeculotomy with the OMNI® Surgical System Compared to Standard Medical Treatment as a Standalone Procedure in Patients with Primary Open Angle Glaucoma (EVOLVE)

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Male or female subjects, 45 years or older.

  2. History of uncomplicated cataract surgery and posterior chamber intraocular lens (IOL) implantation without compromise to the lens capsule, zonulardehiscence/rupture or vitreous prolapse, 6 months or more prior to Baseline Visit (pseudophakic subjects), OR, phakic and no anticipated need for cataract surgeryover the study duration.

  3. Under treatment with a topical prostaglandin F2 analog (e.g. latanoprost,travoprost, bimatoprost, tafluprost) either as monotherapy or in combination withone (1) adjunctive medication for a minimum of 6 weeks prior to the Screening visit.

  4. Intraocular pressure (IOP) at the Screening visit of >18 and not exceeding 36 mmHg.

  5. Diagnosed with primary open angle glaucoma (POAG).

Exclusion

Exclusion Criteria:

  1. Any of the following prior ocular procedures:
  • Laser trabeculoplasty ≤180 days prior to baseline

  • Durysta ≤12 months prior to baseline unless failure is documented and topicalmedication including a prostaglandin analog is in use as per Inclusioncriterion # 3.

  • Implanted with iStent (All types), Cypass, Xen, Express, glaucoma drainingdevice/valve, or Hydrus Device; or

  • Prior canaloplasty, goniotomy, trabeculotomy, trabeculectomy, endoscopiccyclophotocoagulation (ECP), Cyclophotocoagulation or CPC (G probe)

  • Retinal laser procedure ≤3 months prior to baseline

  1. Concurrent IOP-lowering procedure other than the study procedure (OSS) (e.g. ECP,CPC,etc.)

  2. Forms of glaucoma other than POAG including but not limited to: Pigmentary,pseudoexfoliative, acute angle closure, normal tension, pre-perimetric, traumatic,congenital, malignant, uveitic, neovascular or severe glaucoma as documented insubject's medical record.

  3. Women of childbearing potential if they are currently pregnant or intend to becomepregnant during the study period; are breast-feeding; or are not in agreement to useadequate birth control methods to prevent pregnancy throughout the study

Study Design

Total Participants: 2
Treatment Group(s): 2
Primary Treatment: OMNI Surgical System
Phase: 4
Study Start date:
August 21, 2024
Estimated Completion Date:
January 20, 2025

Study Description

This prospective, multicenter, post-market clinical trial will evaluate the safety and effectiveness of canaloplasty and trabeculotomy using the OSS as a standalone procedure in patients with POAG.

Connect with a study center

  • North Bay Eye Associates

    Petaluma, California 94954
    United States

    Site Not Available

  • University Eye Specialists

    Maryville, Tennessee 37803
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.